Passage Bio
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Passage Bio generated cash of -$78,264,000, which is more than the previous year. Cash used in financing activities reached the amount of $135,000 last year. Net change in cash is therefore -$12,892,000.
Cash Flow
| 2018 | -18.56M | -2.54M | 45.97M |
|---|---|---|---|
| 2019 | -39.89M | -1.69M | 175.60M |
| 2020 | -80.52M | -172.10M | 228.75M |
| 2021 | -126.87M | -45.81M | 166.65K |
| 2022 | -118.21M | 25.19M | -1.35K |
| 2023 | -78.26M | 65.23M | 135K |
PASG Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 34.60M | 128.96M | 135.00M | 158.87M | 24.86M | 0 |
Operating activities | ||||||
Net income | -102.06M | -136.12M | -185.38M | -112.23M | -45.63M | -12.77M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 3.72M | 3.67M | 1.54M | 800K | 134K | 0 |
Stock-based compensation expense | 10.92M | 18.95M | 32.69M | 14.58M | 1.45M | 0 |
| Deferred income tax benefit | 10.92M | 18.95M | 32.69M | 14.58M | 1.45M | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 398K | 212K |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -2.79M | -5.41M | 2.20M | 4.58M | 398K | 212K |
Cash generated by operating activities | -78.26M | -118.21M | -126.87M | -80.52M | -39.89M | -18.56M |
Investing activities | ||||||
Purchases Of Investments | -129.43M | -157.83M | -202.54M | -266.05M | 0 | 0 |
Investments In Property Plant And Equipment | -146K | -5.27M | -25.64M | -1.64M | -1.69M | -2.54M |
Acquisitions Net | 0 | 3M | 8M | 500K | 0 | 0 |
Cash generated by investing activities | 65.23M | 25.19M | -45.81M | -172.10M | -1.69M | -2.54M |
Financing activities | ||||||
Common Stock Issued | 135K | 304K | 166.65M | 228.26M | 175.60M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 284K | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 135K | -1.35K | 166.65K | 228.75M | 175.60M | 45.97M |
Net Change In Cash | -12.89M | -94.36M | -6.03M | -23.87M | 134.01M | 24.86M |
Cash at end of period | 21.70M | 34.60M | 128.96M | 135.00M | 158.87M | 24.86M |
| Data source | Data source | Data source | Data source |